$10.63
3.36% day before yesterday
Nasdaq, Dec 27, 09:49 pm CET
ISIN
US09075A1088
Symbol
BVS

Bioventus Inc - Ordinary Shares - Class A Stock price

$10.62
-1.67 13.59% 1M
+4.90 85.66% 6M
+5.35 101.52% YTD
+5.29 99.25% 1Y
-3.35 23.98% 3Y
-2.38 18.31% 5Y
-2.38 18.31% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.38 3.45%
ISIN
US09075A1088
Symbol
BVS
Sector

Key metrics

Market capitalization $694.21m
Enterprise Value $1.08b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 38.89
EV/Sales (TTM) EV/Sales 1.95
P/S ratio (TTM) P/S ratio 1.25
P/B ratio (TTM) P/B ratio 4.67
Revenue growth (TTM) Revenue growth 10.40%
Revenue (TTM) Revenue $555.06m
EBIT (operating result TTM) EBIT $25.06m
Free Cash Flow (TTM) Free Cash Flow $27.87m
Cash position $43.07m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 1.23
EV/Sales forward 1.92
Short interest 2.69%
Show more

Is Bioventus Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Bioventus Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

Buy
67%
Hold
33%

Financial data from Bioventus Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
555 555
10% 10%
100%
- Direct Costs 191 191
5% 5%
34%
364 364
21% 21%
66%
- Selling and Administrative Expenses 276 276
33% 33%
50%
- Research and Development Expense 14 14
20% 20%
2%
75 75
3% 3%
13%
- Depreciation and Amortization 50 50
33% 33%
9%
EBIT (Operating Income) EBIT 25 25
679% 679%
5%
Net Profit -39 -39
78% 78%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Bioventus Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioventus Inc - Ordinary Shares - Class A Stock News

Neutral
Seeking Alpha
about 2 months ago
Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Biove...
Neutral
GlobeNewsWire
about 2 months ago
DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024.
Neutral
GlobeNewsWire
2 months ago
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that sam...
More Bioventus Inc - Ordinary Shares - Class A News

Company Profile

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.

Head office United States
CEO Robert Claypoole
Employees 970
Founded 2011
Website www.bioventus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today